Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07109219 · ClinicalTrials.gov registry record · Phase 1

Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia

A Phase 1 study of B-cell Acute Lymphoblastic Leukemia (B-ALL), sponsored by AstraZeneca.

Recruiting
Registry status
Phase 1
Development phase
83
Enrollment target
20
Study locations

NCT07109219 is a Phase 1 study of B-cell Acute Lymphoblastic Leukemia (B-ALL) that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 83 participants, below the 119-participant average among 6 other B-cell Acute Lymphoblastic Leukemia (B-ALL) trials with a reported enrollment target (30% lower). The trial reports 20 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07109219, a Phase 1 study of B-cell Acute Lymphoblastic Leukemia (B-ALL), is actively recruiting participants, sponsored by AstraZeneca.

RECRUITING
Registry status
Phase 1
Development phase
83 participants
Enrollment target
20
Study locations

Study Summary

The study is intended to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of AZD4512 in patients with relapsed/refractory B-Cell acute lymphoblastic leukemia (r/r B-ALL).

Conditions Studied

B-cell Acute Lymphoblastic Leukemia (B-ALL)

Interventions

  • COMBINATION_PRODUCT AZD4512 monotherapy

Study Locations (20)

Other

  • Research Site - Melbourne
  • Research Site - Guangzhou
  • Research Site - Tianjin
  • Research Site - Bunkyō City
  • Research Site - Chūōku
  • Research Site - Seoul
  • Research Site - Seoul
  • Research Site - Seoul
  • Research Site - Seoul
  • Research Site - Badalona(Barcelona)
  • Research Site - Barcelona
  • Research Site - Salamanca

California

  • Research Site - Duarte

Florida

  • Research Site - Jacksonville

Illinois

  • Research Site - Chicago

Iowa

  • Research Site - Iowa City

Tennessee

  • Research Site - Franklin

Texas

  • Research Site - Houston

British Columbia

  • Research Site - Vancouver

Trial Details

FieldValue
Enrollment Target 83 participants
Start Date 2025-11-12
Est. Completion 2028-07-03
Phase Phase 1

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07109219

The ClinicalTrials.gov registry entry for NCT07109219 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 83 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 119-participant average among 6 other B-cell Acute Lymphoblastic Leukemia (B-ALL) trials with a reported enrollment target (30% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with B-cell Acute Lymphoblastic Leukemia (B-ALL) appearing as the primary indexed condition, and to 1 intervention - of which AZD4512 monotherapy is the first listed.

NCT07109219 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Other, California, Florida.

Frequently Asked Questions

What is clinical trial NCT07109219 about?

NCT07109219 is a clinical study titled "Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia". The study is intended to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of AZD4512 in patients with relapsed/refractory B-Cell acute lymphoblastic leukemia (r/r B-ALL).

What is the current status of trial NCT07109219?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 83 participants. The study started on 2025-11-12. Estimated completion is 2028-07-03.

What conditions does trial NCT07109219 study?

This clinical trial studies the following conditions: B-cell Acute Lymphoblastic Leukemia (B-ALL).

What interventions are being tested in trial NCT07109219?

The interventions under investigation include: AZD4512 monotherapy (COMBINATION_PRODUCT).

Who is sponsoring clinical trial NCT07109219?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07109219 being conducted?

This trial has 20 study locations across California, Florida, Illinois, Iowa, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for B-cell Acute Lymphoblastic Leukemia (B-ALL)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

B-cell Acute Lymphoblastic Leukemia (B-ALL)

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.